PMID- 26189878
OWN - NLM
STAT- MEDLINE
DCOM- 20160428
LR  - 20150720
IS  - 1399-0039 (Electronic)
IS  - 0001-2815 (Linking)
VI  - 86
IP  - 2
DP  - 2015 Aug
TI  - Human leukocyte antigens and genetic susceptibility to lymphoma.
PG  - 98-113
LID - 10.1111/tan.12604 [doi]
AB  - Familial aggregation, coupled with ethnic variation in incidence, suggests that 
      inherited susceptibility plays a role in the development of lymphoma, and the 
      search for genetic risk factors has highlighted the contribution of the human 
      leukocyte antigen (HLA) complex. In a landmark study published almost 50 years 
      ago, Hodgkin lymphoma (HL) was the first disease to be associated with HLA 
      variation. It is now clear that Epstein-Barr virus (EBV)-positive and -negative 
      HL are strongly associated with specific HLA polymorphisms but these differ by 
      EBV status of the tumours. HLA class I alleles are consistently associated with 
      EBV-positive HL while a polymorphism in HLA class II is the strongest predictor 
      of risk of EBV-negative HL. Recent investigations, particularly genome-wide 
      association studies (GWAS), have also revealed associations between HLA and 
      common types of non-Hodgkin lymphoma (NHL). Follicular lymphoma is strongly 
      associated with two distinct haplotypes in HLA class II whereas diffuse large 
      B-cell lymphoma is most strongly associated with HLA-B*08. Although chronic 
      lymphocytic leukaemia is associated with variation in HLA class II, the strongest 
      signals in GWAS are from non-HLA polymorphisms, suggesting that inherited 
      susceptibility is explained by co-inheritance of multiple low risk variants. 
      Associations between B-cell derived lymphoma and HLA variation suggest that 
      antigen presentation, or lack of, plays an important role in disease pathogenesis 
      but the precise mechanisms have yet to be elucidated.
CI  - (c) 2015 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.
FAU - McAulay, K A
AU  - McAulay KA
AD  - MRC - University of Glasgow Centre for Virus Research, Institute of Infection, 
      Immunity and Inflammation, College of Medical, Veterinary and Life Sciences, 
      University of Glasgow, Glasgow, UK.
FAU - Jarrett, R F
AU  - Jarrett RF
AD  - MRC - University of Glasgow Centre for Virus Research, Institute of Infection, 
      Immunity and Inflammation, College of Medical, Veterinary and Life Sciences, 
      University of Glasgow, Glasgow, UK.
LA  - eng
PT  - Journal Article
PT  - Review
PL  - England
TA  - Tissue Antigens
JT  - Tissue antigens
JID - 0331072
RN  - 0 (Histocompatibility Antigens Class I)
RN  - 0 (Histocompatibility Antigens Class II)
SB  - IM
MH  - Alleles
MH  - Epstein-Barr Virus Infections/complications/*genetics/immunology/pathology
MH  - Gene Expression
MH  - *Genetic Predisposition to Disease
MH  - Genome-Wide Association Study
MH  - Haplotypes
MH  - Herpesvirus 4, Human/pathogenicity/physiology
MH  - Histocompatibility Antigens Class I/*genetics/immunology
MH  - Histocompatibility Antigens Class II/*genetics/immunology
MH  - Hodgkin Disease/complications/*genetics/immunology/pathology
MH  - Humans
MH  - Lymphoma, Non-Hodgkin/complications/*genetics/immunology/pathology
MH  - Polymorphism, Single Nucleotide
OTO - NOTNLM
OT  - B-cell lymphoma
OT  - Epstein-Barr virus
OT  - Hodgkin lymphoma
OT  - human leukocyte antigen
EDAT- 2015/07/21 06:00
MHDA- 2016/04/29 06:00
CRDT- 2015/07/21 06:00
PHST- 2015/07/21 06:00 [entrez]
PHST- 2015/07/21 06:00 [pubmed]
PHST- 2016/04/29 06:00 [medline]
AID - 10.1111/tan.12604 [doi]
PST - ppublish
SO  - Tissue Antigens. 2015 Aug;86(2):98-113. doi: 10.1111/tan.12604.